Category: Publications

Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial

Posted on by Delphine Renaud

Jacques Donnez, M.D., Ph.D., Hugh S. Taylor, M.D., Ph.D., Robert N. Taylor, M.D., Ph.D., Mark D. Akin, M.D., Tatyana F. Tatarchuk, M.D., Dr. Sc., Krzysztof Wilk, M.D., Jean-Pierre Gotteland, Ph.D., Veronique Lecomte, Pharm.D., Elke Bestel, M.D.

Published online: June 03, 2020

Donnez, Jacques et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial. Fertility and Sterility, Volume 114, Issue 1, July 2020, Pages 44-55

Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis

Posted on by Delphine Renaud

Olivier Donnez M.D., Ph.D. , Jacques Donnez M.D., Ph.D.

Published online: June 02, 2020

Donnez, Olivier et al. Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis. Fertility and Sterility, Volume 114, Issue 3, September 2020, Pages 640-645

Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern

Posted on by Delphine Renaud

Pohl O., Marchand L., Bell D., Gotteland JP.

Pohl O, Marchand L, Bell D, Gotteland JP. Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern. Reprod Sci. 2020;27(4):988‐995. doi:10.1007/s43032-020-00172-z

Babies Born Following Administration of Nolasiban Before Embryo Transfer (ET) After IVF: Neonatal and Infant Development Outcomes From a Double-Blind, Placebo-Controlled, Clinical Trial

Posted on by Delphine Renaud

Humberstone A., Terrill P., Macgregor L., Loumaye E.

ASRM 2019 Scientific Congress & Expo, 12-16 October 2019, Philadelphia, PA

Fertility and Sterility Vol. 112, No. 3, Supplement, September 2019. Abstract on pages e7-e8.

Long Term Treatment of Endometriosis Associated Pain (EAP) With Linzagolix: Efficacy and Safety After 12 Months of Treatment

Posted on by Delphine Renaud

Taylor R., Bestel E., Gotteland JP., Lecomte V., Dubouloz R., Terrill P., Humberstone A., Loumaye E.

ASRM 2019 Scientific Congress & Expo, 12-16 October 2019, Philadelphia, PA

Fertility and Sterility Vol. 112, No. 3, Supplement, September 2019. Abstract on page e323.

Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F2α-induced Contractions and Inflammatory Responses in Human Myometrium

Posted on by Sylwia Scheel-Krüger

Sung Hye Kim, Lucia Riaposova, Hauwa Ahmed, Oliver Pohl, André Chollet, Jean-Pierre Gotteland, Aylin Hanyaloglu, Phillip R. Bennett & Vasso Terzidou

Kim SH, Riaposova L, Ahmed H, et al. Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F2α-induced Contractions and Inflammatory Responses in Human Myometrium. Sci Rep. 2019;9(1):5792. Published 2019 Apr 8. doi:10.1038/s41598-019-42181-2

Co‐administration of the prostaglandin F2α receptor antagonist pre‐term labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone

Posted on by Sylwia Scheel-Krüger

Oliver Pohl, Line Marchand, Jean‐Pierre Gotteland, Simon Coates, Jörg Täubel, Ulrike Lorch

Pohl, O, Marchand, L, Gotteland, J‐P, Coates, S, Täubel, J, Lorch, U. Coadministration of the prostaglandin F2α receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone. Br J Clin Pharmacol. 2019; 85: 1516– 1527.https://doi.org/10.1111/bcp.13925

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue